For instance, Agonists such as APG350, AMP655 targeting TRAIL (tumor necrosis factor (TNF) related apoptosis-inducing ligand) receptor signaling could selectively induce cancer cell apoptosis in mice models but limited benefits was observed in cancer patients (81–86). This evidence concerns the gene TNFSF10 and cancer.